Editors: Atta-ur-Rahman , M. Iqbal Choudhary

Frontiers in Anti-Infective Drug Discovery

Volume 4

eBook: US $109 Special Offer (PDF + Printed Copy): US $185
Printed Copy: US $131
Library License: US $436
ISSN: 2451-9162 (Print)
ISSN: 1879-663X (Online)
ISBN: 978-1-68108-083-3 (Print)
ISBN: 978-1-68108-082-6 (Online)
Year of Publication: 2015
DOI: 10.2174/97816810808261150401


This eBook series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the eBook series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships.

Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field.

The fourth volume of this series features 5 chapters that cover the following topics:

  • - An overview of the incidence of neuraminadase resistance in influenza viruses in the Americas from 2004 to 2014
  • - Phenothiazines and derivative compounds for treating Trypanosoma cruzi infections
  • - New antibacterial drug targets such as polysaccharide deacetylases
  • - Improvements in aminoglycoside synthesis and biological activity (including RNA targeting)
  • - A review of new chemotherapeutic agents against common infections.

Indexed in: Book Citation Index, Science Edition, BIOSIS Previews, Scopus, EMBASE, EBSCO, Ulrich's Periodicals Directory.


Infectious diseases continue to be an enduring threat to human survival and well-being. The recent Ebola epidemic in Western Africa has revealed a number of limitations at every front, including lack of timely response, improper disease surveillance, failure of national governments to control epidemics and most importantly, the failure of the pharmaceutical industry to develop a single effective drug for a disease which is known to be so deadly since the last four decades. This is indeed an early warning for other deadlier future epidemics which may soon emerge.

Continuous research on new potent anti-infective drugs, and efforts to understand infections at the molecular level to identify new drug targets are urgently needed. The 4th volume of the eBook series “Frontiers in Anti-Infective Drug Discovery” is therefore timely and important. It is a compilation of five well written chapters, contributed by leading practitioners in the field.

The chapter by Fornells and Couceiro provides details of the emerging resistance against flu treatments with anti-neuraminidase drugs. The presence of mutations in the influenza virus, responsible for producing resistance against anti-neuraminidase drugs, is discussed in detail.

Drug repositioning is an important approach for drug discovery and development. Oliva et al. have conducted extensive studies on the use of the anti-depressant drugs, such as phenothiliazines as anti-trypanosomal drugs. Trypanosoma cruzi is the causative agent of a common parasitic tropical disease, called Chagas disease. These well known anti-depressant drugs exert their trypanocidal effects by inhibiting trypanothione reductase, an enzyme which is essential for the redox defense system of the parasite. This article provides strong support for the drug repositioning / repurposing approach, i.e. for finding new health benefits in old drugs.

Bouriotis et al. have reviewed the current state of research with respect to bacterial polysaccharide deacetylases as drug targets for antibacterial drug development. Polysaccharide deacetylase plays an important role in the bacterial life cycle, and its inhibition is an important approach towards the development of new anti-bacterial drugs.

Revuelta et al. present a review on the potential of RNA-binding drugs as anti-infectious agents. They describe the use of positively charged aminoglycoside class of compounds that bind with ribosomal RNA, and can serve as anti-bacterial agents. These compounds can also be used as antiviral drugs against other diseases.

Finally, Boso-Ribelles et al. have contributed a comprehensive review on the changing landscape of antibiotic development, which does not seem very promising. They summarize the outcomes of several drug discovery initiatives, new antibiotics in the pipeline, and current state of research on old drugs to develop new antibiotics. This chapter, in brief, is a charge sheet on the negligence towards this important field, which is now causing tremendous human suffering.

This volume is the result of hard work of many eminent researchers. We wish to express our profound gratitude to them. We would also like to acknowledge the dedication and hard work of the excellent team of Bentham Science Publishers, led by Mr. Mahmood Alam, Director of Bentham Science Publishers. The efforts of Ms. Fariya Zulfiqar, Assistant Manager Publications, deserve special appreciation.

Prof. Atta-ur-Rahman, FRS

Honorary Life Fellow
Kings College
University of Cambridge

Prof. M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi


.COVID-19: Current Challenges and Future Perspectives.
.Tuberculosis: A Clinical Practice Guide  .
.The COVID-19 Pandemic: Epidemiology, Molecular Biology and Therapy.
.Frontiers in Clinical Drug Research- HIV.